SCHEMBL19677809

SCHEMBL19677809

CCCCCCCCCCCCCCCC(=O)N1CCCC1C(=O)NCCCCC(NC(=O)C1CCCN1C(=O)CCCCCCCCCCCCCCC)C(=O)NCCN

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.52
SIRT6 Q8N6T7 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.43
PRCP P42785 1/20 0.42
NTMT1 Q9BV86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19677801 1.00 APLNR (0.52) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL19677807 1.00 APLNR (0.52) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL19677785 1.00 APLNR (0.52) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL21167058 0.98 APLNR (0.52) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL21705523 0.97 APLNR (0.53) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL21527471 0.96 APLNR (0.49) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL19677790 0.96 SIRT6 (0.53) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL24111250 0.95 MEN1 (0.54) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL19677808 0.91 APLNR (0.48) APLNRSIRT6SIRT1MEN1TP53
SCHEMBL24140111 0.91 MEN1 (0.50) APLNRSIRT6SIRT1MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid ADOCIA (FR) 2023-07-25 US disclosed
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID ADOCIA (FR) 2018-07-12 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid ADOCIA (FR) 2017-12-07 US disclosed
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID ADOCIA (FR) 2017-12-07 US disclosed
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid ADOCIA (FR) 2017-12-07 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID ADOCIA (FR) 2017-12-07 US disclosed
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID IAPP, GPR119, GIPR APLNR 16/4885SIRT6 3619/4885SIRT1 3630/4885
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR APLNR 1847/4885SIRT6 3384/4885SIRT1 4244/4885
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID GCG, GLP1R, IAPP APLNR 662/4885SIRT6 844/4885SIRT1 1823/4885
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid GCG, GLP1R, IAPP APLNR 671/4885SIRT6 1034/4885SIRT1 1847/4885
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid IAPP, INSR, GLP1R APLNR 23/4885SIRT6 3723/4885SIRT1 3437/4885
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, F7, GIPR APLNR 1129/4885SIRT6 2765/4885SIRT1 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.